Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154205 | 0.93 | GPR119 (0.54) | GPR119IRAK4CNR1ALDH1A1MAPT | |
| SCHEMBL6153585 | 0.84 | ALDH1A1 (0.52) | GPR119IRAK4USP30MEN1KMT2A | |
| SCHEMBL7189717 | 0.81 | GPR119 (0.54) | GPR119IRAK4USP30ALDH1A1MAPT | |
| SCHEMBL7178322 | 0.81 | GPR119 (0.54) | GPR119IRAK4USP30ALDH1A1MAPT | |
| SCHEMBL7178327 | 0.81 | GPR119 (0.54) | GPR119IRAK4USP30ALDH1A1MAPT | |
| SCHEMBL29136118 | 0.81 | ALDH1A1 (0.53) | GPR119IRAK4USP30MEN1KMT2A | |
| SCHEMBL6154769 | 0.80 | CHEK2 (0.51) | GPR119USP30MEN1KMT2ACNR1 | |
| SCHEMBL30952425 | 0.80 | IRAK4 (0.51) | GPR119IRAK4USP30CNR1CNR2 | |
| SCHEMBL7182933 | 0.78 | GPR119 (0.51) | GPR119IRAK4USP30KMT2AALDH1A1 | |
| SCHEMBL7182925 | 0.78 | GPR119 (0.51) | GPR119IRAK4USP30KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GPR119 279/4885IRAK4 3240/4885USP30 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.